The activities and impact of state programs to address hereditary breast and ovarian cancer, 2011–2014

Healthcare (Switzerland)

Volumn 3, Issue 4, 2015, Pages 948-963

  Trivers, Katrina F ^a   Rodriguez, Juan L ^a   Cox, Summer L ^b   Crane, Barbara E ^c   Duquette, Debra ^d  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b OREGON HEALTH AUTHORITY   (United States)

^c GEORGIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

BRCA; Breast cancer; Genetic services; Genomics; Hereditary breast; Implementation; Ovarian cancer; State health departments

Indexed keywords

EID: 85006034069     PISSN: None     EISSN: 22279032     Source Type: Journal    
DOI: 10.3390/healthcare3040948     Document Type: Article

References (31)

1. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 2000, 83, 1301–1308.
2. Antoniou, A.C.; Gayther, S.A.; Stratton, J.F.; Ponder, B.A.; Easton, D.F. Risk models for familial ovarian and breast cancer. Genet. Epidemiol. 2000, 18, 173–190.
3. Antoniou, A.C.; Pharoah, P.D.; McMullan, G.; Day, N.E.; Stratton, M.R.; Peto, J.; Ponder, B.J.; Easton, D.F. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br. J. Cancer 2002, 86, 76–83.
4. Peto, J.; Collins, N.; Barfoot, R.; Seal, S.; Warren, W.; Rahman, N.; Easton, D.F.; Evans, C.; Deacon, J.; Stratton, M.R. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst. 1999, 91, 943–949.
5. Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117–1130.
6. Chen, S.; Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007, 25, 1329–1333.
7. Domchek, S.M.; Friebel, T.M.; Singer, C.F.; Evans, D.G.; Lynch, H.T.; Isaacs, C.; Garber, J.E.; Neuhausen, S.L.; Matloff, E.; Eeles, R.; et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304, 967–975.
8. Skytte, A.B.; Cruger, D.; Gerster, M.; Laenkholm, A.V.; Lang, C.; Brondum-Nielsen, K.; Andersen, M.K.; Sunde, L.; Kolvraa, S.; Gerdes, A.M. Breast cancer after bilateral risk-reducing mastectomy. Clin. Genet. 2011, 79, 431–437.
9. Evans, D.G.; Gaarenstroom, K.N.; Stirling, D.; Shenton, A.; Maehle, L.; Dorum, A.; Steel, M.; Lalloo, F.; Apold, J.; Porteous, M.E.; et al. Screening for familial ovarian cancer: Poor survival of BRCA1/2 related cancers. J. Med. Genet. 2009, 46, 593–597.
10. Nelson, H.D.; Smith, M.E.; Griffin, J.C.; Fu, R. Use of medications to reduce risk for primary breast cancer: A systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2013, 158, 604–614.
11. Moyer, V.A. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2014, 160, 271–281.
12. National Comprehensive Cancer Network. Available online: www.nccn.org (accessed on 31 August 2015).
13. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann. Intern. Med. 2005, 143, 355–361.
14. Frieden, T.R. Six components necessary for effective public health program implementation. Am. J. Public Health 2014, 104, 17–22.
15. St Pierre, J.; Bach, J.; Duquette, D.; Oehlke, K.; Nystrom, R.; Silvey, K.; Zlot, A.; Giles, R.; Johnson, J.; Anders, H.M.; et al. Strategies, actions, and outcomes of pilot state programs in public health genomics, 2003–2008. Prev. Chronic Dis. 2014, 11, 1–9.
16. Topics and Objectives-Objectives A–Z. Available online: http://www.healthypeople.gov/2020/topicsobjectives2020/default (accessed on 31 August 2015).
17. Patient Protection and Affordable Care Act. Available online: http://legcounsel.house.gov/Comps/Patient%20Protection%20And%20Affordable%20Care%20Act.pdf (accessed on 31 August 2015).
18. Science Impact. Available online: http://www.cdc.gov/od/science/impact/(accessed on 31 August 2015).
19. The Institute of Medicine: What Makes It Great? President’s Address, Institute of Medicine Annual Meeting. Available online: http://iom.nationalacademies.org/~/media/Files/About%20the%20IOM/PresidentsAddress2013.pdf (accessed on 31 August 2015).
20. Advisory Committee on Breast Cancer in Young Women (ACBCYW). Enhancing Breast Cancer Genomics Best Practices and Policies in the State of Michigan. Available online: http://www.michigan.gov/documents/mdch/ACBCYW2014_SM_jvb_477688_7.pdf (accessed on 31 August 2015).
21. Hereditary Breast and Ovarian Cancer: Is Your Patient at Risk? Available online: http://www.nchpeg.org/hboc/(accessed on 31 August 2015).
22. Inside Knowledge: Get the Facts About Gynecologic Cancer. Available online: http://www.cdc.gov/cancer/knowledge/(accessed on 31 August 2015).
23. Breast Cancer in Young Women. Available online: http://www.cdc.gov/cancer/breast/young_ women/index.htm (accessed on 31 August 2015).
24. Bellcross, C. Further development and evaluation of a breast/ovarian cancer genetics referral screening tool. Genet. Med. 2010, doi:10.1097/GIM.0b013e3181d4bc3a.
25. Bellcross, C.A.; Lemke, A.A.; Pape, L.S.; Tess, A.L.; Meisner, L.T. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet. Med. 2009, 11, 783–789.
26. Breast Cancer Genetics Referral Screening Tool (B-RST™). Available online: https://www.breast cancergenescreen.org/(accessed on 31 August 2015).
27. Brannon Traxler, L.; Martin, M.L.; Kerber, A.S.; Bellcross, C.A.; Crane, B.E.; Green, V.; Matthews, R.; Paris, N.M.; Gabram, S.G. Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: A statewide initiative. Ann. Surg. Oncol. 2014, 21, 3342–3347.
28. Cox, S.; George, R.; Soule, J.; Parkman, A.; Kovak, K.; Patil, M.; Shipley, D. Increasing awareness of hereditary breast and ovarian cancer syndrome (HBOC) among survivors and their providers through the Oregon State Cancer Registry (OSCaR). In Proceedings of the 7th Biennial Survivorship Conference, Atlanta, GA, USA, 7 July 2014.
29. Shipley, D.; Patil, M.; Soule, J.; Evangelista, S.; Cox, S.; George, R.; Parkman, A.; Kovak, K. Oregon’s approach to increasing awareness of hereditary breast and ovarian cancer syndrome (HBOC) among clinicians and patients. In Proceedings of the NAACCR Annual Conference, Ottawa, ON, Canada, 24 June 2014.
30. H.R.83—Consolidated and Further Continuing Appropriations Act. Available online: https://www.congress.gov/bill/113th-congress/house-bill/83 (accessed on 31 August 2015).
31. Genomics Application Toolkit. Available online: http://www.cdc.gov/genomics/implementation/toolkit/tier1.htm (accessed on 31 August 2015).